NASDAQ:REGN

Regeneron Pharmaceuticals Stock Forecast, Price & News

$653.18
+1.18 (+0.18 %)
(As of 09/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$643.38
$656.67
50-Day Range
$574.03
$680.96
52-Week Range
$441.00
$686.62
Volume494,228 shs
Average Volume871,542 shs
Market Capitalization$69.86 billion
P/E Ratio11.73
Dividend YieldN/A
Beta0.16
30 days | 90 days | 365 days | Advanced Chart
Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Regeneron Pharmaceuticals logo

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.55 out of 5 stars

Medical Sector

79th out of 1,352 stocks

Pharmaceutical Preparations Industry

36th out of 665 stocks

Analyst Opinion: 2.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

Is Regeneron Pharmaceuticals a buy right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 4 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Regeneron Pharmaceuticals stock.
View analyst ratings for Regeneron Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Regeneron Pharmaceuticals?

Wall Street analysts have given Regeneron Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Regeneron Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Regeneron Pharmaceuticals
.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) released its quarterly earnings results on Thursday, August, 5th. The biopharmaceutical company reported $25.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.81 by $16.99. The biopharmaceutical company earned $5.14 billion during the quarter, compared to analysts' expectations of $3.90 billion. Regeneron Pharmaceuticals had a net margin of 50.11% and a trailing twelve-month return on equity of 50.43%.
View Regeneron Pharmaceuticals' earnings history
.

How has Regeneron Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, REGN stock has increased by 40.6% and is now trading at $653.18.
View which stocks have been most impacted by COVID-19
.

How will Regeneron Pharmaceuticals' stock buyback program work?

Regeneron Pharmaceuticals announced that its Board of Directors has approved a share buyback plan on Tuesday, November 5th 2019, which permits the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 2.9% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's board believes its shares are undervalued.

What price target have analysts set for REGN?

17 brokerages have issued 12 month target prices for Regeneron Pharmaceuticals' stock. Their forecasts range from $565.00 to $831.00. On average, they anticipate Regeneron Pharmaceuticals' share price to reach $698.38 in the next year. This suggests a possible upside of 6.9% from the stock's current price.
View analysts' price targets for Regeneron Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the following people:
  • Leonard S. Schleifer, Co-President, Chief Executive Officer & Director
  • George Damis Yancopoulos, Co-President, Director & Chief Scientific Officer (LinkedIn Profile)
  • Patrice Gilooly, Senior VP-Quality Assurance & Operations
  • Robert E. Landry, Chief Financial Officer & Executive VP-Finance
  • Neil Stahl, Executive VP-Research & Development

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals CEO Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among Regeneron Pharmaceuticals' employees.

Who are some of Regeneron Pharmaceuticals' key competitors?

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), The Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and salesforce.com (CRM).

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (10.24%), BlackRock Inc. (8.48%), Vanguard Group Inc. (7.48%), State Street Corp (4.22%), Geode Capital Management LLC (1.60%) and Northern Trust Corp (1.09%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marion Mccourt, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van and Robert E Landry.
View institutional ownership trends for Regeneron Pharmaceuticals
.

Which major investors are selling Regeneron Pharmaceuticals stock?

REGN stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., BlackRock Inc., ARK Investment Management LLC, Susquehanna International Group LLP, Swiss National Bank, Nuveen Asset Management LLC, Woodline Partners LP, and AQR Capital Management LLC. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Arthur F Ryan, Bonnie L Bassler, George L Sing, George Yancopoulos, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Marion Mccourt, Michael S Brown, P Roy Vagelos, Plew Daniel P Van, and Robert E Landry.
View insider buying and selling activity for Regeneron Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Regeneron Pharmaceuticals stock?

REGN stock was bought by a variety of institutional investors in the last quarter, including Putnam Investments LLC, Amundi, Point72 Asset Management L.P., Bank of Nova Scotia, Canada Pension Plan Investment Board, Geode Capital Management LLC, Nikko Asset Management Americas Inc., and Mn Services Vermogensbeheer B.V..
View insider buying and selling activity for Regeneron Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $653.18.

How much money does Regeneron Pharmaceuticals make?

Regeneron Pharmaceuticals has a market capitalization of $69.86 billion and generates $8.50 billion in revenue each year. The biopharmaceutical company earns $3.51 billion in net income (profit) each year or $28.66 on an earnings per share basis.

How many employees does Regeneron Pharmaceuticals have?

Regeneron Pharmaceuticals employs 9,123 workers across the globe.

Does Regeneron Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Regeneron Pharmaceuticals: Loop Road Holdings LLC, OSMR Holdings, OSMR International, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.

When was Regeneron Pharmaceuticals founded?

Regeneron Pharmaceuticals was founded in 1988.

What is Regeneron Pharmaceuticals' official website?

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

Where are Regeneron Pharmaceuticals' headquarters?

Regeneron Pharmaceuticals is headquartered at 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at (914) 847-7000 or via email at [email protected]


This page was last updated on 9/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.